Oxford center aims to increase clinical trial success rate

05/7/2013 | Bloomberg · PharmaTimes (U.K.)

A new research center at the University of Oxford aims to reduce the midstage clinical trial failure rate, which stands at about 90%. Hong Kong billionaire Li Ka-Shing and the U.K. government donated about $31 million each to fund the Li Ka-Shing Centre for Health Information and Discovery, with the goal of using data from patient records, genomic sequencing, clinical trials and national registries to help doctors make better decisions. Drugmakers Eli Lilly & Co., GlaxoSmithKline, Pfizer, Johnson & Johnson, Boehringer Ingelheim, Novartis, AbbVie and Takeda are giving $8 million each to the Target Discovery Institute at Oxford in an effort to find innovative targets for drug development.

View Full Article in:

Bloomberg · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN